Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mannitol increases plasma osmolality, drawing water from tissues into the intravascular space via osmotic gradient, thereby reducing intracranial pressure and promoting diuresis. Dextrose provides caloric support. Sodium chloride provides electrolytes.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Reduction of intracranial pressure (FDA approved),Promotion of diuresis in acute renal failure (FDA approved),Reduction of intraocular pressure (off-label),Cerebral edema (off-label),Enhancement of urinary excretion of toxic substances (off-label)
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous: 50 to 100 g (333-667 m L) initially, then 50 g (333 m L) every 4-6 hours to maintain urine output of 30-50 m L/hr. Administer as a 15% solution with dextrose 5% in 0.45% sodium chloride.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Mannitol: 0.5-1.5 hours in normal renal function; prolonged to 24-48 hours in anuria; dextrose: 1-2 hours; negligible for sodium chloride.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Mannitol is minimally metabolized in the liver; mainly excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis. Approximately 80% of mannitol is excreted in urine within 3 hours.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal excretion of unchanged mannitol: 80-90% within 24 hours; dextrose is fully metabolized; sodium chloride is renally excreted.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Mannitol: 0% (not bound to plasma proteins); dextrose: negligible; sodium chloride: not applicable.
Low protein binding; 0–11% bound, primarily to albumin.
Mannitol: 0.2-0.5 L/kg, primarily extracellular; dextrose: ~0.2 L/kg; sodium chloride distributes in extracellular fluid.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
IV: 100% for all components; no oral bioavailability for mannitol (<10% absorbed).
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). Use with caution in oliguria; monitor urine output and renal function.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific adjustment required; use with caution in severe hepatic impairment due to fluid and electrolyte balance concerns.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
200 mg/kg to 2 g/kg as a 15% solution intravenously over 2-6 hours, not to exceed 60 g in 24 hours. Adjust based on urine output and clinical response.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Start at lower end of dosing range; monitor renal function, fluid and electrolyte status due to age-related decline in renal function.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
No FDA boxed warning.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Monitor serum electrolytes, renal function, and fluid balance,Risk of pulmonary edema or congestive heart failure in patients with cardiac disease,Risk of acute kidney injury or renal tubular necrosis with excessive doses or prolonged use,May cause fluid and electrolyte disturbances (e.g., hyponatremia, hyperkalemia),Use with caution in patients with impaired renal function,Intravenous administration: avoid extravasation, use large vein, monitor for phlebitis
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Anuria or severe renal impairment,Pulmonary edema or congestive heart failure,Active intracranial bleeding (except during craniotomy),Dehydration or hypovolemia,Known hypersensitivity to mannitol or any component
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No known food interactions. However, patients may require sodium restriction depending on their condition.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
No evidence of teratogenicity in animal studies. Use in pregnancy only if clearly needed. Mannitol crosses placenta; fetal effects may include electrolyte disturbances and dehydration. Avoid in first trimester unless benefit outweighs risk. In second and third trimesters, monitor for maternal pulmonary edema and fetal distress.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Mannitol likely excreted in breast milk due to low molecular weight. No M/P ratio available. Use with caution in lactating women; consider risk of infant dehydration or electrolyte imbalance. May suppress lactation due to diuretic effect.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy increases glomerular filtration rate, potentially enhancing mannitol clearance. No specific dose adjustment guidelines; titrate to clinical response and serum osmolality. Monitor for hypovolemia and electrolyte disturbances. Use lowest effective dose.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Monitor urine output and serum sodium closely; mannitol can cause osmotic diuresis leading to hypernatremia or hyponatremia depending on fluid status. Administer via central line due to high osmolality; extravasation causes tissue necrosis. Contraindicated in anuria, pulmonary edema, and intracranial bleeding. Use with caution in renal impairment and heart failure.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This medication may increase urination; keep track of how much you urinate.,Report any chest tightness, difficulty breathing, or swelling.,You may experience dry mouth or thirst; maintain adequate fluid intake if allowed.,This solution is for intravenous use only; do not inject into muscle or under skin.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Mannitol increases plasma osmolality, drawing water from tissues into the intravascular space via osmotic gradient, thereby reducing intracranial pressure and promoting diuresis. Dextrose provides caloric support. Sodium chloride provides electrolytes.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% is: Intravenous: 50 to 100 g (333-667 m L) initially, then 50 g (333 m L) every 4-6 hours to maintain urine output of 30-50 m L/hr. Administer as a 15% solution with dextrose 5% in 0.45% sodium chloride.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% is classified as Category A/B. No evidence of teratogenicity in animal studies. Use in pregnancy only if clearly needed. Mannitol crosses placenta; fetal effects may include electrolyte disturbances and dehydrat. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.